World Health Organization recommendations for multidrug-resistant tuberculosis : should different standards be applied?
The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals, they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen.
| Errataetall: |
ErratumIn: Int J Tuberc Lung Dis. 2018 Mar 1;22(3):353-354. - PMID 29471916 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease - 21(2017), 12 vom: 01. Dez., Seite 1211-1213 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
|---|
| Links: |
|---|
| Themen: |
78846I289Y |
|---|
| Anmerkungen: |
Date Completed 11.01.2019 Date Revised 11.01.2019 published: Print ErratumIn: Int J Tuberc Lung Dis. 2018 Mar 1;22(3):353-354. - PMID 29471916 Citation Status MEDLINE |
|---|
| doi: |
10.5588/ijtld.17.0199 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279606494 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279606494 | ||
| 003 | DE-627 | ||
| 005 | 20231225023353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5588/ijtld.17.0199 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0932.xml |
| 035 | |a (DE-627)NLM279606494 | ||
| 035 | |a (NLM)29297439 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cox, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a World Health Organization recommendations for multidrug-resistant tuberculosis |b should different standards be applied? |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2019 | ||
| 500 | |a Date Revised 11.01.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Int J Tuberc Lung Dis. 2018 Mar 1;22(3):353-354. - PMID 29471916 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The World Health Organization uses a Grading of Recommendations Assessment, Development, and Evaluation process to make recommendations for treating multidrug-resistant tuberculosis. Even with this standardized approach, there have been discrepancies between recommendations for newer drugs such as bedaquiline and delamanid and the shorter regimen. This may be because newer drugs are novel chemical entities and may merit closer scrutiny. Here, we explore the problematic nature of this supposition, arguing that although the newer drugs have been used in fewer individuals, they may have more robust efficacy and safety data than many of the second-line drugs used in the shorter regimen | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Diarylquinolines |2 NLM | |
| 650 | 7 | |a Nitroimidazoles |2 NLM | |
| 650 | 7 | |a OPC-67683 |2 NLM | |
| 650 | 7 | |a Oxazoles |2 NLM | |
| 650 | 7 | |a bedaquiline |2 NLM | |
| 650 | 7 | |a 78846I289Y |2 NLM | |
| 700 | 1 | |a Furin, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease |d 1998 |g 21(2017), 12 vom: 01. Dez., Seite 1211-1213 |w (DE-627)NLM093757409 |x 1815-7920 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2017 |g number:12 |g day:01 |g month:12 |g pages:1211-1213 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5588/ijtld.17.0199 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2017 |e 12 |b 01 |c 12 |h 1211-1213 | ||